Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Overview

Información sobre este estudio

The primary purpose of this dose-ranging study is to assess the safety and tolerability of 3 ascending doses of LX2006 gene therapy for the purpose of selecting the appropriate dose for further clinical development. In addition, assessments of biomarkers and preliminary efficacy are included in this study.

The primary purpose of the LTFU is to assess the long-term safety and tolerability of LX2006 up to 5 years post-treatment. Additionally, efficacy assessments will be evaluated quarterly during Year 2 and annually up to 5 years post-treatment.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Confirmed genetic diagnosis of Friedreich’s Ataxia (FA), with onset being before 25 years of age.
  • Protocol specified ranges for antibodies.
  • Protocol specified measures of FA cardiomyopathy.

Exclusion Criteria:

  • Protocol specified ranges for left ventricular ejection fraction (LVEF) as measured by cardiac ECHO.
  • Uncontrolled diabetes.
  • Abnormal liver function.
  • Active infection of any type, including hepatitis virus (A, B or C) or human immunodeficiency virus (HIV-1 and HIV-2).
  • Contraindication to cardiac MRI.
  • Contraindications to cardiac biopsies.
  • Participants who are receiving systemic corticosteroids or other immunosuppressive medications.
  • History of significant coronary artery disease or any structural heart or vascular disease other than FA cardiomyopathy.
  • Presence of clinically significant, hemodynamically unstable arrhythmias, requiring physician intervention.
  • Presence of clinically significant abnormalities as determined by the investigator, other than ECG abnormalities related to FA.
  • Uncontrolled psychiatric disease.

Other Inclusion/Exclusion Criteria to be applied as per protocol.

Eligibility last updated 7/13/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Ralitza Gavrilova, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Clinical Genomics Research

(507) 293-9114

RSTCGRESEARCH@mayo.edu

More information

Publicaciones

Publications are currently not available